Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

04:03 EDT 25th August 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

With First Trials On Horizon, Value Of Growing Philly Xarelto Claims Uncertain

It might be more than a year from now, but litigation centered on the blood thinner Xarelto could eventually come to trial in Philadelphia courtrooms – and one attorney says the thousands of cases f...

Venous Thromboembolism therapeutics market set to hit $3.7 bn by 2025

Biospectrum Pradaxa, Xarelto, and Eliquis, which are all currently available, will see improved uptake over the forecas...

Portola's anticoagulant antidote gets EU review

Portola has said European regulators are to review its anticoagulant antidote, IndexXa (andexanet alfa), just days after the US regulator rejected the drug. California-based Portola said the Europea...

Lawyers Accuse J&J and Bayer of Withholding Xarelto Study Data

Lawyers for patients suing Johnson & Johnson and Bayer over severe bleeding injuries caused by the blockbuster blood thinner Xarelto say the drug makers failed to provide clinical trial data, th...

The potential of reversal agents for target-specific oral anticoagulants

After more than 60 years of having only warfarin as an option for oral anticoagulation, several target-specific oral anticoagulants have entered the market.These agents include a direct thrombin inhib...

Bayer's Xarelto projected to become top-selling drug in Europe by 2022

Although Xarelto is an older drug, expanded indications and a new reversal agent could boost sales in Europe.Globally, however, the drug is predicted to fall well out of the top-ten drugs by sale...

Xarelto Clinical Trial Likened To 'Science Fair Project' By Philly Malpractice Lawyer

The quality and depth of clinical trials of the blood-thinner Xarelto could be a key issue when the first trials over the drug begin in Philadelphia courtrooms. With the first trial of more than 800 l...

FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules

[03-29-2011] The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate) capsules.

Matching PubMed Articles

Praxbind Available as Antidote to Bleeding from Pradaxa.

Pharmaceutical Approval Update.

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for ...

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is ...

Bilateral Spontaneous Hyphema, Vitreous Hemorrhage, and Choroidal Detachment With Concurrent Dabigatran Etexilate Therapy.

A 79-year-old woman was referred for rapid onset of painless bilateral vision loss. Anterior segment exams revealed bilateral spontaneous hyphema and fibrin accumulation. Observation of the posterior ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement